• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/15

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

15 Cards in this Set

  • Front
  • Back
How do ADDs modulate monoamine transmission?
By increasing synaptic transmitter concentrations and desensitizing various monoamine receptors
What is the MONOAMINE RECEPTOR HYPOTHESIS?
Changes in biogenic amine receptor fxn, rather than in absolute transmitter levels, are the underlying cause of depression.
What besides monoaminergic transmission is dysregulated in depression?
The HPA axis
What inhibits the HPA axis?
The hippocampus
What excites the HPA axis?
The amygdala
How does stress-induced elevation of glucocorticoid levels affect the fxn of the hippocampus?
It can cause hippocampal dysfunction and famage, with further increases circulating glucocorticoid levels.
What is BDNF?
BDNF (brain derived neurotropic factor) provides trophic support of hippocampal neurons.
What effect do ADDs have on BDNF levels?
they increase the hippocampal BDNF expression.
What is the role of the ventral tegmental area (VTA)?
It mediates rewarding responses to external stimuli.
What are the fxns of D1 and 5 receptors?
They ↑ the level of cAMP, whereas D2-4 ↓ intracellular cAMP.
What do D2 receptors do?
They ↑ K+ channel conductance and ↓ Ca2+ channel conductance.
How is 5HT3 different from the other 13 receptors?
Only 5HT3 opens a Ca2+ channel while the others activate second messenger cascades.
What is the fxn of 5HT1A receptors?
They reduce the firing rate
What is the fxn of 5HT1D receptors?
They inhibit the release of 5HT (control the amt. released)
What are the 6 broad categories of antidepressant drugs?
Monoamine oxidase (MAO) inhibitors, Tri- and Tera-cyclic antidepressants (TCAs), SSRIs, Second generation atypical antidepressants, third generation heterocyclics, and mood stabilizers.